Morgan Keegan Reports on EW Sapien Approval

Morgan Keegan has issued a report that Edwards Lifesciences Corporation's EW Sapien was approved by the Circulatory Devices Advisory Panel. According to ther report, "The panel seemed relatively satisfied that the benefit of the Sapien valve was significant enough in the studied population to justify its use, but repeatedly urged caution before expanding the indication to larger populations." EW has a Market Perform Rating and a $97 Price Target. EW closed at $87.53 yesterday.